Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial-Reference-Cited by-同舟云学术

Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial

Published:2020-10 Issue:10 Volume:26 Page:1569-1575
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Shah Nirav N.^ORCID,Johnson Bryon D.,Schneider Dina,Zhu Fenlu,Szabo Aniko^ORCID,Keever-Taylor Carolyn A.^ORCID,Krueger Winfried,Worden Andrew A.,Kadan Michael J.,Yim Sharon^ORCID,Cunningham Ashley,Hamadani Mehdi^ORCID,Fenske Timothy S.,Dropulić Boro^ORCID,Orentas Rimas,Hari Parameswaran

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-020-1081-3.pdf

Reference32 articles.

1. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

2. Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2018).

3. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).

4. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

5. Tran, E., Longo, D. L. & Urba, W. J. A milestone for CAR T cells. N. Engl. J. Med. 377, 2593–2596 (2017).

Cited by 310 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

2. Fratricide-resistant CD7-CAR T cells in T-ALL;Nature Medicine;2024-09-03

3. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

4. T cell-redirecting therapies in hematological malignancies: Current developments and novel strategies for improved targeting;Molecular Therapy;2024-09

5. CD28 hinge used in chimeric antigen receptor (CAR) T-cells exhibits local structure and conformational exchange amidst global disorder;Communications Biology;2024-08-31